Panic disorder, a type of anxiety disorder, is characterized by recurrent, unexpected panic attacks and a persistent fear of future attacks. The prevalence of anxiety disorders is projected to reach 4565.65 per 100,000 people by 2030. Current first-line treatments include selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines. However, there remains a significant unmet clinical need for more effective therapies, as these options often come with side effects and limited long-term efficacy. The growing focus on developing innovative treatments, including novel drug classes and personalized medicine, is expected to drive pipeline growth in the coming years.
The Panic Disorder Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into panic disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for panic disorder. The panic disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The panic disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with panic disorder treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to panic disorder.
Panic disorder is an anxiety disorder marked by recurrent, unexpected panic attacks which is an intense episode of fear that peaks within minutes. These attacks often lead to persistent worry about future attacks and significant behavioral changes. Panic disorder can occur due to genetic factors, stress, or brain chemistry imbalances.
Panic disorder is primarily treated with selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and cognitive behavioral therapy. SSRIs help regulate mood, while benzodiazepines provide rapid relief. However, long-term solutions are being explored through new drug classes and targeted therapies.
The global prevalence of anxiety disorders, including panic disorder, is projected to rise significantly, reaching 4565.65 per 100,000 people by 2030 and 5752.68 by 2050. In the United States, around 19.1% of adults experience anxiety disorders annually, including panic disorder. In India, the increase in anxiety disorder prevalence ranges from 23.7% to 35%. These trends underscore a growing need for advanced treatments.
This section of the report covers the analysis of panic disorder drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total panic disorder clinical trials.
The drug molecule categories covered under the panic disorder pipeline analysis include small molecules, biologics, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for panic disorder.
The EMR panic disorder drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in panic disorder clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for panic disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of panic disorder drug candidates.
The study, sponsored by Sultan Qaboos University, aims to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. This Phase 4 study will assess the feasibility, effectiveness, and side effects of hydroxyzine. Expected to conclude by December 2026, the study will enroll around 80 participants to provide valuable insights for future research.
The Phase 2 clinical trial sponsored by Honeybrains Biotech LLC aims to evaluate the safety and efficacy of HB-1 for treating panic disorder. This multicenter, randomized, double-blind, placebo-controlled study will involve approximately 240 participants, aged 18 to 65, with panic disorder. The study is expected to be completed by February 2026, with primary results anticipated in January 2026.
Cerevel Therapeutics, LLC is sponsoring a Phase 2 clinical trial to assess the efficacy, safety, and tolerability of darigabat (25 mg twice daily) in participants with panic disorder, compared to a placebo. The study, enrolling approximately 246 participants, started in July 2023 and is expected to be completed by April 2025, with primary results anticipated by March 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Panic Disorder Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for panic disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into panic disorder collaborations, regulatory environments, and potential growth opportunities.
Anxiety and Depression Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share